Albireo Pharma
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.
Show more...
CEO
Mr. Ronald H. W. Cooper
Employees
90
Country
United States
ISIN
US01345P1066
WKN
000A2DF99
Listings
0 Comments
Share your thoughts
FAQ
What is Albireo Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Albireo Pharma stocks are traded under the ticker BDQM.MU.
How many employees does Albireo Pharma have?▼
As of September 04, 2026, the company has 90 employees.
In which sector is Albireo Pharma located?▼
Albireo Pharma operates in the Health & Wellness sector.
When did Albireo Pharma complete a stock split?▼
Albireo Pharma has not had any recent stock splits.
Where is Albireo Pharma headquartered?▼
Albireo Pharma is headquartered in Boston, United States.